Tech Company Financing Transactions
Epitopea Funding Round
adMare BioInnovations, Advent Life Sciences and Cambridge Innovation Capital joined a $31 million Series A venture round for Epitopea. The financing round closed on 10/24/2024.
Transaction Overview
Company Name
Announced On
10/24/2024
Transaction Type
Venture Equity
Amount
$31,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds for the strategic development and clinical entry of lead Cryptigen immunotherapeutics.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Salisbury House, Station Road
Cambridge, CB1 2LA
United Kingdom
Cambridge, CB1 2LA
United Kingdom
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
We are a global leader in exploiting a novel class of untapped tumour-specific antigens (TSAs), CryptigenTM TSAs, designed to treat a broad patient population
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Co-Founder
Claude Perreault
Co-Founder
Pierre Thibault
Browse more venture capital transactions:
Prev: 10/24/2024: Skyfire venture capital transaction
Next: 10/25/2024: Speckle venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to document every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs